tumor burden

tu·mor bur·den

the total mass of tumor tissue carried by a patient with a malignancy.

tu·mor bur·den

(tū'mŏr bŭr'dĕn)
The total mass of tumor tissue carried by a patient with cancer.
Synonym(s): tumour burden.

tumor burden

The sum of cancer cells present in the body.
References in periodicals archive ?
The trial demonstrated equivalence in overall response rate for the first-line treatment of patients with CD20-positive, low tumor burden, follicular lymphoma.
One of the OMM dogs showed obvious tumor regression after 10 weeks of administration, while one dog with undifferentiated sarcoma showed a significant decrease in tumor burden after three weeks.
Changes in tumor burden and IMDC class after active surveillance (AS) for metastatic renal cell carcinoma (mRCC).
Cancer is a highly complex disease, so the ability to obtain a complete and accurate genomic profile of malignant tumors and monitor changes in tumor burden is invaluable.
b2m seems to reflect tumor burden of malignant cells Pathological specifications and clinical data showed a significant change between controls and NHL with and without bone marrow infiltration.
This strategy is the least likely one to succeed, because the tumor burden may already be overwhelming, and the number of molecular aberrations in the cancer too vast and varied to be overcome by simple targeting strategies.
The tumor burden in the discordant cases was evenly distributed in the intermediate-high-risk group as follows: mild (tumor burden 1) in 40% (n = 14), moderate (tumor burden 2) in 44.
Although ctDNA concentrations have been found to vary considerably among patients with the same tumor types, the relative cfDNA mutation levels within an individual have been shown to correlate with tumor burden and response to cytotoxic chemotherapy (2).
It helps to expand targeted therapy treatment options, predict response to immune-checkpoint inhibitors and utilize ctDNA based assay to monitor tumor burden and resistant markers, in their CAP-accredited NGS laboratory through its full spectrum of clinical service.
Conventional response criteria such as RECIST might underestimate benefit of immune checkpoint blockade, such as ipilimumab and pembrolizumab, because objective response and prolonged disease stabilization can occur after an initial increase in tumor burden or new lesions.
1) Therefore, obtaining negative margins prior to radiation therapy is the primary goal of breast-conserving surgery, and minimizing the microscopic residual tumor burden through removal of larger amounts of normal breast tissue has traditionally been considered a major factor for optimizing local control.
They cross the blood-brain/blood-tumor barrier, and accumulate within brain tumor sites, where they target oncogenes, regulate cell growth and differentiation, reduce tumor burden and prolong survival in our mouse models.